The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.

Caldera, a Web3 infrastructure platform that helps developers deploy Ethereum rollups for scaling up blockchain networks, today announced it has raised $15 million in an early-stage funding round.

1.2 million years ago: A major volcanic explosion forms a caldera in what is now the Jemez Mountains as the earth around the volcano collapses into the drained magma chamber. Over the next million ...